QIBA fMRI Biomarker Committee Call Summary  
Wednesday, March 23, 2016 at 11 AM CDT  

Call Summary

In attendance
James Reuss, PhD (Co-Chair)  
Feroze Mohamed, PhD  
Kirk Welker, MD  

RSNA
Joe Koudelik

Edward Jackson, PhD  
David Soltysik, PhD  
Yuxiang Zhou, PhD, DABR  

In attendance
James Reuss, PhD (Co-Chair)  
Feroze Mohamed, PhD  
Kirk Welker, MD  

RSNA
Joe Koudelik

Edward Jackson, PhD  
David Soltysik, PhD  
Yuxiang Zhou, PhD, DABR  

In attendance
James Reuss, PhD (Co-Chair)  
Feroze Mohamed, PhD  
Kirk Welker, MD  

RSNA
Joe Koudelik

Edward Jackson, PhD  
David Soltysik, PhD  
Yuxiang Zhou, PhD, DABR  

Moderator: Dr. Reuss

Review of Previous Call Summary
- The 03.09.2016 call summary was approved as presented

Profile 1.0 status draft (Dr. Mohamed, et al.)
- Drs. Mohamed, DeYoe and Pillai have been working on various aspects of this document
- Dr. Elsinger converted Profile 1.0 to the latest Profile template, which can be found on the QIBA Wiki at: http://qibawiki.rsna.org/index.php?title=Main_Page
- Remaining open issues were identified and collated for efficient internal committee review/discussion
- The table of contents is complete, but page numbers need to be updated
- RSNA staff to distribute Profile to core fMRI BC members for review prior to QIBA Annual Meeting breakout sessions
- Dr. Mohamed to collect all feedback on Profile 1.0 for discussion on the last fMRI BC call (April 6) before the QIBA Annual Meeting
- Profile v1.0 will be out for public comment by Summer 2016

Profile 2.0 general discussion of scope (all)
- Issues unable to be addressed in version 1.0 will be revisited in 2.0
- Language to be Profile v2.0 focus

NIBIB Round-6 – prepare concepts for BC consideration (all)
- High-level project concepts should be submitted directly to BC leaders asap
- The deadline for proposal submissions (including budget sheet) is April 15
- Dr. Pillai to propose a Round-6 project
- Because QIBA has continued to grow, the funding process for Year 6 projects may be more competitive
- Discussion on funding for feasibility testing continues
- Funds cannot be used for prospective human subject studies, but may be used for retrospective reviews/analysis of human subject studies
- After publically reviewed the Profile will be technically-confirmed, which means that details have been implemented in more than one facility and each individual actor (system and person) successfully met the specifications
- DROs may be used to conduct field testing and as part of the Profile conformance process
- Some QIBA groups have developed automated software packages (scripts) to analyze DRO data results
• To discuss further at the QIBA Annual Meeting: prospect of working with cooperative groups for human studies to prove Claims

• Two aspects to proving Claim:
  o Statistical: prove with DROs and standard data sets
  o Validation: Profile serves purpose that is claimed it does, in practice

Breakout Agenda for QIBA Annual Meeting: April 13-14, 2016 (all)

• Separate breakout session agendas for day 1 and day 2 to be drafted and then solidified on next fMRI BC call on April 6

• The majority of breakout session time will be spent discussing open issues in Profile v1.0

Next calls:

• QIBA fMRI Bias TF call - Tuesday, March 29 at 10am CDT
• QIBA fMRI Biomarker Committee call - Wednesday, April 6 at 11am CDT